Researchers identify eight new active molecules against Alzheimer

Researchers of the Unit of Medicine Design and Molecular Topology (Department of Physics Chemistry) of the University of Valencia (UV) have discovered eight new active molecules against Alzheimer by a novel mechanism of action, different to the currently used medicines. The work has just been published in the "Plos One" magazine.

One of the most relevant aspects of the work is that the new molecules have been designed following a mechanism which not only implies the inhibition of the deposit of the beta-amyloid protein, which causes the disease to originate and the creation of small fragments of protein, called oligomers, which originate in the initial stages of the disease and seem to play a determinant role in the development of the process.

The director of the team, the full university professor Jorge Galvez, specifies that molecules have been designed "following a methodology called molecular topology, the team has been working on that methodology since the Eighties".

The laboratory testing which have confirmed the activity of the new molecules have been carried out by the prestigious Mount Sinai School of Medicine of New York, under the direction of Giulio M. Pasinetti, professor of neurology in the at that centre and director of the Centre of Excellence for complementary treatment of Alzheimer of that institution. In the tests on molecules, which have shown activity both in vitro (neuronal cellular cultures) and in live (in transgenic mice), it has also taken part Japanese and North American researchers.

The group of Medicine Design and Molecular Topology of the UV has worked under the leadership of the professors Gálvez y García-Domenech in the design of many other kinds of medicines (including anticancer medicines, antihistamines, analgesics, food additives and pesticide residues, quoting some examples) being authors of more than a hundred of scientific publications on the issue in international magazines, as well as several national and international patents. According to Jorge Galvez, "this information demonstrates that nce more molecular typology is a potent tool to the design of new medicines and, in general, of new active molecules in different applications, including agriculture, food, etc…"

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UCLA researchers discover netrin1's unexpected role in spinal cord development